Erythema multiforme-like papules after COVID vaccine administration

Theodore J Daly1, Gregory T Smith, Steve A McClain

  • 1Garden City Dermatology, Garden City, New York, USA. dalyt100@gmail.com.

PubMed

Insights

A rare case of purpuric interface dermatitis occurred after the Moderna mRNA-1273 vaccine. This skin condition, presenting as red spots and rash-like symptoms, resolved without lasting effects.

Area of Science:

  • Dermatology
  • Immunology
  • Vaccinology

Background:

  • The widespread use of mRNA vaccines like mRNA-1273 (Moderna) for SARS-CoV-2 has prompted investigation into potential adverse cutaneous reactions.
  • Understanding vaccine-related dermatological events is crucial for public health and patient safety.

Observation:

  • A patient presented with a unique dermatopathology incident following the second dose of the mRNA-1273 vaccine.
  • The presentation included transient purpuric interface dermatitis with erythematous papules and erythema multiforme-like features.
  • The onset of symptoms was noted 5 days post-vaccination.

Findings:

  • The patient developed purpuric interface dermatitis characterized by micro-vesiculation.
  • The observed dermatological reaction was transient and resolved completely.
  • No long-term sequelae were reported following the resolution of the skin condition.

Implications:

  • This case highlights a rare, self-limiting cutaneous side effect associated with the mRNA-1273 SARS-CoV-2 vaccine.
  • Further research may be needed to elucidate the immunopathological mechanisms underlying vaccine-induced purpuric interface dermatitis.
  • Clinicians should be aware of this potential dermatological manifestation in post-vaccination assessments.